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Abstract
Trials in the 1990s demonstrated that medical therapy is as effective as invasive therapies for
treating single-vessel coronary disease. Yet more recent studies enrolling patients with this
condition have focused on evaluating only invasive approaches, namely, stenting versus coronary
artery bypass surgery. Several ethical and scientific questions remain unanswered regarding the
conduct of these later trials. Were they justified? Why wasn't a medical therapy arm included?
Were subjects informed about the availability of medical therapy as an equivalent option? Was
optimized medical therapy given prior to randomization? The absence of clear answers to these
questions raises the possibility of serious bias in favor of invasive interventions. Considering that
medical therapy is underutilized in patients with coronary disease, efforts should focus more on
increasing utilization of medical therapy and proper selection of noninvasive interventions.
Introduction
Two recent (2002) trials of surgical vs. percutaneous inter-
ventions for coronary disease [1,2] raise serious questions
about the conduct of research that focuses on manage-
ment of coronary artery disease [CAD]. In both of these
studies, symptomatic patients with proximal left anterior
descending [LAD] stenosis – supposedly the stenosis site
associated with the highest risk – experienced similar out-
comes with stenting or with minimally invasive bypass
surgery. These results leave the impression that physicians
now have several properly validated invasive options
from which to choose when treating patients with single-
vessel CAD. This misleading perception ignores previous
research on the efficacy of medical therapy in treating this
condition, thereby casting doubt upon the ethical and sci-
entific merits of these trials.
Unanswered questions in light of prior research
In the 1990s, two well-designed trials compared medical
and invasive approaches for treating single-vessel CAD. In
the ACME study, death and infarction rates were similar
with either medical therapy or with angioplasty, although
angioplasty was associated with greater relief of angina
[3]. The landmark MASS study focused on patients with
high-grade proximal LAD stenosis [4]. Again, rates of
death or infarction as well as abolition of limiting angina
were similar with medical therapy, angioplasty or bypass
surgery.
Published: 29 March 2004
Current Controlled Trials in Cardiovascular Medicine 2004, 5:2
Received: 21 December 2003
Accepted: 29 March 2004
This article is available from: http://cvm.controlled-trials.com/content/5/1/2
© 2004 Jabbour et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all 
media for any purpose, provided this notice is preserved along with the article's original URL.Current Controlled Trials in Cardiovascular Medicine 2004, 5 http://cvm.controlled-trials.com/content/5/1/2
Page 2 of 3
(page number not for citation purposes)
In the 2002 trials, one of which received funding from
industry, subjects were randomized to either stenting or to
minimally invasive bypass surgery [2] (a medical therapy
arm was not included). Several questions remain unan-
swered regarding the ethical justification for conducting
these later trials. Were they really needed? Didn't the 1990
trials already demonstrate the equivalence of medical and
invasive approaches for treating single-vessel CAD,
including proximal LAD stenosis? The fact that we now
have new invasive techniques is not per se sufficient reason
for new trials to be conducted without concrete evidence
that these techniques actually save more lives and prevent
more infarctions. The populations studied were low risk
by virtue of having chronic stable angina and normal left
ventricular function. These cohorts would have done well
on medical therapy. Why was medical therapy excluded
from comparison? It seems that investigators had already
decided that medical therapy was not as effective as the
invasive strategies. Did these investigators ever tell their
patients that medical therapy was equivalent to invasive
interventions, based on previous research? Without this
information, patients would not have been truly informed
about all effective treatment options, when asked to con-
sider joining either of the 2002 trials. Furthermore, rates
of cardiac death or myocardial infarction were 3–6% with
stenting and 6–10% with bypass in the recent studies.
These rates are higher than those reported in the 1990
studies or in recent trials of aggressive lipid-lowering
agents in similar populations [5]. Therefore, the risks
associated with the proposed invasive approaches cannot
be assumed to be minimal.
There are also unanswered scientific questions regarding
the more recent studies. Why wasn't intensive and tailored
medical therapy tried before proceeding to randomiza-
tion? Instead of committing valuable resources to conduct
trials of newer and more costly interventions, efforts
should focus on ensuring that everyone with CAD, espe-
cially those with limited access to health care, receives
appropriate medical treatment. What was the medical
therapy strategy after interventions? Aggressive medica-
tion use and risk factor modification could have reduced
the relatively high event rates observed post-intervention
in these trials, and may well have obviated the need for
invasive interventions in the first place.
Another concern relates to the need for coronary angiog-
raphy. Neither study describes the presence and severity of
ischemia. Diegeler et al. do not even mention level of
angina or use of anti-anginal medications prior to referral.
Why were patients referred for angiography in the first
place? It is probably too late to contemplate whether med-
ications or revascularization is better once high-grade
stenoses are detected. The interventionist almost always
recommends "doing something". The treating physician,
who commonly underestimates the efficacy of medica-
tions and overestimates the value of interventions, [6] is
under pressure to follow the recommendation. The
patient, who senses grave danger when hearing 90% or
95% stenosis (especially when coupled with the doctor's
own anxiety), has no alternative but to "choose" an inter-
vention. This is the path through which coronary angiog-
raphy becomes a funnel for subsequent revascularization.
Medical therapy has no chance here.
Favoring invasive approaches to CAD: Evidence 
from other settings
Investigator preference of invasive interventions over
medical therapies for single-vessel CAD seems to extend
to management of CAD in general. Several recent publica-
tions illustrate our case. The investigators of two recent
studies favored invasive approaches to CAD in the elderly,
despite outstanding results with medical therapy. In the
TIME study, medically treated patients had slightly less
overall risk of death and experienced no significant
increase in risk of myocardial infarction after 6 months of
therapy compared to those treated invasively, a remarka-
ble finding considering that 31% of subjects had class IV
angina [7]. Reassuringly, participants in both treatment
arms experienced reduced angina and improved quality of
life to a similar extent, while clinical events remained
comparable at 1 year [8]. Similarly, Graham et al. [9]
observed comparable outcomes with medical and inva-
sive therapy among elderly patients. Why the authors of
both studies chose to overstate the benefits of an invasive
approach based on their own findings escapes us. [10] A
balanced commentary justifiably questioned whether
medical therapy was really optimal in these studies, but it
failed to recommend optimizing medical therapy, which
evidence already supports as the primary course of action
in elderly patients with stable CAD [11].
Similarly, the debate over invasive vs. non-invasive ther-
apy for acute coronary syndromes [ACS] exposes serious
biases in favor of invasive therapy. Although a report of
the RITA 3 trial found similar rates of death and myocar-
dial infarction with both approaches, it overstated the
benefits of invasive therapy in reducing refractory angina
[12-14]. Certainly, patients with refractory symptoms
need revascularization, but the exception should not
become the rule. Given the equivalent effects of medical
and invasive interventions on clinical events, the latter
should be reserved for certain situations, e.g., for patients
who are refractory to maximal medical therapy or for
those with high risk indicators. An early invasive strategy
for everyone with ACS makes no scientific, ethical, or eco-
nomic sense.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Current Controlled Trials in Cardiovascular Medicine 2004, 5 http://cvm.controlled-trials.com/content/5/1/2
Page 3 of 3
(page number not for citation purposes)
Towards an alternative approach
It is the process leading to coronary angiography where we
most need to focus in order to improve care and prevent
unnecessary interventions. In the absence of high-risk
indicators, maximal, intensive and tailored medical ther-
apy, coupled with aggressive risk factor modification,
should be the first choice of action. The provocation of
mild-to-moderate ischemia or angina in patients taking
submaximal doses of medications is not an adequate indi-
cation for coronary angiography. By the same token, when
coronary angiography is performed, and single-vessel
CAD stenosis is detected, the first question that should
come to mind is not which invasive intervention is better
but whether medical therapy has been given a fair chance.
There is ample evidence in the medical literature that this
more conservative approach is not being followed prop-
erly [15]. The recent trials provide no new information
that would lead us to disregard medical therapy as an
effective and safe option for treating the patient with prox-
imal LAD stenosis. On the contrary, the burden of proof is
still on those advocating an invasive approach. If patients
are told that an invasive approach is no more effective
than medical therapy in preventing death or infarction or
in abolishing limiting angina (and that medical interven-
tion might even lead to more anginal relief), how many
patients would still choose to undergo interventions that
are costly and not free of complication? In addition,
improvement in medical therapies since the two 1990
studies were published means potentially more benefits
using a more conservative approach.
At a time when more studies are showing benefits of
grossly underutilized medical therapies, we need to re-
evaluate the current processes of peer review of studies of
invasive management of CAD by research funding agen-
cies and scientific journals. The purpose here is not to
make adversaries but rather to detect subtleties that can
uncover biases and correct them for the benefit of both
patients and science. This is the only way for us to find
balanced approaches for management of CAD. We
encourage everyone to think together of more effective
mechanisms than the occasional letter to the Editor.
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